Parkinson's Stem Cell Therapy: Japan's iPS Product, Insurance and First Transplant

Summary — Parkinson's stem cell therapy is entering routine care in Japan. Amchepry (raguneprocel), a product made of dopaminergic neural progenitor cells derived from another person's induced pluripotent stem (iPS) cells, was added to Japan's public health insurance in May 2026, and an August 2026 report said the first transplant was scheduled for October at Kyoto University Hospital. Abroad, three-year results of an embryonic stem cell-derived therapy were presented at the American Academy of Neurology (AAN) meeting in April 2026. This article summarises Japanese and overseas announcements from the past six months on how far Parkinson's stem cell research has come.

Parkinson's disease and current standard treatment

Parkinson's disease (Japanese パーキンソン病) is a neurodegenerative disease in which dopamine-producing nerve cells in the substantia nigra of the midbrain are gradually lost, leading to motor symptoms such as tremor, slowness of movement, muscle rigidity and walking difficulty. Standard treatment is medication centred on levodopa, which replaces the missing dopamine, with surgery such as deep brain stimulation (DBS) added when needed. As the disease progresses, the effect of each dose often becomes shorter and 'OFF' time increases, which is why cell therapy aiming to replace the lost dopamine neurons has long been studied. For an overview of the disease and research, see the Parkinson's stem cell information page.

Amchepry, an iPS cell product for Parkinson's — insurance coverage in Japan

According to the Japanese pharmaceutical journal Iyaku Tsushinsha and Kyodo News (13 May 2026), the Central Social Insurance Medical Council (Chuikyo), an advisory body to the Ministry of Health, Labour and Welfare, approved insurance coverage for Amchepry, developed by Sumitomo Pharma. The price was set at 55,306,737 yen per patient and the product was listed on 20 May 2026. It is the first iPS cell product listed under Japan's public insurance, and reports described it as the world's first practical use of iPS cell-based regenerative medicine. Japan's high-cost medical expense system, which caps out-of-pocket costs once medical bills exceed a set amount, also applies.

It is indicated for patients with Parkinson's disease who do not obtain sufficient benefit from existing drug therapy including levodopa, for 'improvement of motor symptoms'. According to Sumitomo Pharma's June 2026 information sheet for healthcare professionals, the cells are transplanted into the putamen on both sides of the brain by stereotactic surgery (reaching a precise target through a small hole in the skull). The product received 'conditional and time-limited approval' in March 2026 based on an investigator-initiated trial at Kyoto University Hospital.

The first transplant and the post-marketing trial

The Yomiuri Shimbun (1 August 2026), citing Sumitomo Pharma, reported that the first transplant was scheduled for October 2026 at Kyoto University Hospital, with 35 patients planned by the first half of fiscal 2029. According to Iyaku Tsushinsha, these 35 patients form a post-marketing clinical trial (phase 4): 30 patients aged 18 to 65, followed by 5 patients over 65 once the first 30 transplants are complete. Up to six months may pass from registration to surgery, and seven sites are planned. After two years of follow-up, the company plans to apply for full approval in fiscal 2032.

The information sheet states that all treated patients will be included in post-marketing surveillance and that the product will be supplied only to institutions cooperating with the phase 4 trial. It is covered by the ministry's Optimal Use Promotion Guideline, which sets patient and facility requirements, and it must be used by physicians experienced in Parkinson's care and stereotactic surgery at institutions with an appropriate treatment system. The conditional approval lasts no more than seven years; if efficacy and safety are confirmed again within that period, it becomes a full approval. Japan's conditional approval system is explained in our timeline of regenerative medicine in Japan.

Parkinson's stem cell research abroad — three-year results of an embryonic stem cell-derived therapy

Parkinson's stem cell research is also advancing in the United States. According to Parkinson's News Today (22 April 2026), three-year results of the phase 1 exPDite trial (NCT04802733) of BlueRock Therapeutics' bemdaneprocel were presented at the AAN 2026 Annual Meeting. The therapy transplants dopaminergic neuron precursors made from human embryonic stem cells into the brain; 12 adults who had motor fluctuations on standard treatment took part. Five received a low dose (0.9 million cells per side) and seven a high dose (2.7 million cells per side), and all took immunosuppressants for one year after transplant.

In the low-dose group, motor scores (MDS-UPDRS Part III) remained stable over three years, while the high-dose group showed a trend towards improvement both on and off medication. Home diaries in the high-dose group also tended to show less OFF time and more 'ON' time without troublesome dyskinesia. Annual PET scans showed that the transplanted cells remained engrafted and alive in year three. The presenter described an excellent safety profile, with most adverse events mild to moderate. Participants moved into an extension study with follow-up of up to five years.

Research stage and the next steps

Taken together, these reports show where Parkinson's stem cell therapy stands. In Japan, Amchepry has conditional, time-limited approval and is starting to be used under insurance, and a post-marketing trial collecting data from every treated patient will confirm efficacy and safety in more patients. In the US, building on the three-year phase 1 results, the phase 3 exPDite-2 trial (NCT06944522) is randomising about 102 participants to the high dose or sham surgery in the US, Canada and Australia, with ON time without troublesome dyskinesia as the main outcome. Because phase 1 involved 12 people, controlled phase 3 results will show the size of the benefit more precisely. It helps to read 'improvement was reported' and 'efficacy was proven' as different statements.

Frequently asked questions

Who can receive iPS cell therapy for Parkinson's?

Under the approved indication, patients with Parkinson's disease whose motor symptoms are not adequately controlled by existing drugs including levodopa. For now the product is supplied only to institutions taking part in the phase 4 trial, which plans to enrol 30 patients aged 18 to 65 and 5 patients over 65. Specific conditions are set by the Optimal Use Promotion Guideline and each institution, and whether it suits an individual is decided by the treating medical team.

How much does it cost, and is it covered by insurance?

The Japanese price is 55,306,737 yen per patient, and it has been covered by Japan's public health insurance since 20 May 2026. People enrolled in Japanese insurance have an out-of-pocket cap under the high-cost medical expense system; the actual amount depends on the insurance plan and income category.

How is this different from research using bone marrow stem cells or exosomes?

Amchepry and bemdaneprocel turn iPS or embryonic stem cells into dopaminergic neural progenitors that are transplanted directly into the brain to replace lost nerve cells. Research with bone marrow stem cells (mesenchymal stem cells), stem cell conditioned media or exosomes mainly focuses on anti-inflammatory or neuroprotective effects, so the cell type, route of delivery and research stage differ.

Conclusion

In Japan, an iPS cell product for Parkinson's is now covered by insurance and preparing for its first transplant, and in the US a phase 3 trial is under way based on three-year results of an embryonic stem cell-derived therapy. As results from more patients accumulate in the phase 4 and phase 3 trials, it will become clearer which patients benefit. Suitability and risks of any treatment are judged by the treating medical team, and we will update this summary from the original sources as new results are published. For other brain research, see our article on intravenous bone marrow stem cells for stroke.

This article summarises public reports, company materials and conference presentations. Names of companies, universities and medical institutions are given only to identify sources and are not an introduction or recommendation of any medical institution. Suitability of treatment is judged by the treating medical team.

Brain Disorders (Stroke, Parkinson's, Dementia, ALS, MS) →